IHS Chemical Week

Chemical Week Magazine :: Companies

SemBioSys, Roslin Institute Make Proteins from GM Organisms

12:59 PM MDT | July 25, 2007 | Alex Scott

Biotechnology firm SemBioSys Genetics (Calgary, AB) says it has demonstrated that it can produce insulin for the treatment of diabetes by growing insulin in genetically modified (GM) safflower plants. The insulin is indistinguishable from human insulin, SemBioSys says. SemBioSys says its proprietary GM plant technology will revolutionize the economics associated with producing insulin. Eli Lilly, Novo Nordisk, and Sanofi-Aventis currently dominate the insulin market, which in 2005 was worth $7.2 billion. The company says its technology would reduce manufacturing...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa